Tuberculous Pleurisy Highlighting the Need to Consider Primary Tuberculosis in Interferon-gamma Release Assay-negative Patients.

Intern MedFeb 24, 2026 (epub)

Saki Takeda, Tatsuya Nagai, Taiki Kawai et al.

✦ AI-curated · Sources linked

Case in brief

A 54-year-old man with suspected tuberculous pleurisy initially had a negative interferon-gamma release assay (IGRA) and elevated pleural fluid adenosine deaminase (ADA). Pleural fluid culture subsequently grew Mycobacterium tuberculosis, providing bacteriological confirmation. The IGRA became positive approximately two months after symptom onset. The case illustrates how early testing may not establish or exclude the diagnosis: culture confirmed tuberculosis while the initial IGRA was negative, and later testing showed a change in IGRA status.

What made this case unusual

The IGRA was initially negative but became positive approximately two months after symptom onset, while pleural fluid culture later confirmed tuberculosis.

Diagnostic / clinical pearl

In suspected tuberculous pleurisy, an early negative IGRA does not exclude tuberculosis; interpret IGRA and pleural fluid ADA in context and consider culture for confirmation.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.